Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy.
Alpha-synuclein
Multiple system atrophy
RT-QuIC
Seeding behavior
Journal
Translational neurodegeneration
ISSN: 2047-9158
Titre abrégé: Transl Neurodegener
Pays: England
ID NLM: 101591861
Informations de publication
Date de publication:
07 02 2022
07 02 2022
Historique:
received:
29
09
2021
accepted:
19
01
2022
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Multiple system atrophy (MSA) is a neurodegenerative condition characterized by variable combinations of parkinsonism, autonomic failure, cerebellar ataxia and pyramidal features. Although the distribution of synucleinopathy correlates with the predominant clinical features, the burden of pathology does not fully explain observed differences in clinical presentation and rate of disease progression. We hypothesized that the clinical heterogeneity in MSA is a consequence of variability in the seeding activity of α-synuclein both between different patients and between different brain regions. The reliable detection of α-synuclein seeding activity derived from MSA using cell-free amplification assays remains challenging. Therefore, we conducted a systematic evaluation of 168 different reaction buffers, using an array of pH and salts, seeded with fully characterized brain homogenates from one MSA and one PD patient. We then validated the two conditions that conferred the optimal ability to discriminate between PD- and MSA-derived samples in a larger cohort of 40 neuropathologically confirmed cases, including 15 MSA. Finally, in a subset of brains, we conducted the first multi-region analysis of seeding behaviour in MSA. Using our novel buffer conditions, we show that the physicochemical factors that govern the in vitro amplification of α-synuclein can be tailored to generate strain-specific reaction buffers that can be used to reliably study the seeding capacity from MSA-derived α-synuclein. Using this novel approach, we were able to sub-categorize the 15 MSA brains into 3 groups: high, intermediate and low seeders. To further demonstrate heterogeneity in α-synuclein seeding in MSA, we conducted a comprehensive multi-regional evaluation of α-synuclein seeding in 13 different regions from 2 high seeders, 2 intermediate seeders and 2 low seeders. We have identified unexpected differences in seed-competent α-synuclein across a cohort of neuropathologically comparable MSA brains. Furthermore, our work has revealed a substantial heterogeneity in seeding activity, driven by the PBS-soluble α-synuclein, between different brain regions of a given individual that goes beyond immunohistochemical observations. Our observations pave the way for future subclassification of MSA, which exceeds conventional clinical and neuropathological phenotyping and considers the structural and biochemical heterogeneity of α-synuclein present. Finally, our methods provide an experimental framework for the development of vitally needed, rapid and sensitive diagnostic assays for MSA.
Sections du résumé
BACKGROUND
Multiple system atrophy (MSA) is a neurodegenerative condition characterized by variable combinations of parkinsonism, autonomic failure, cerebellar ataxia and pyramidal features. Although the distribution of synucleinopathy correlates with the predominant clinical features, the burden of pathology does not fully explain observed differences in clinical presentation and rate of disease progression. We hypothesized that the clinical heterogeneity in MSA is a consequence of variability in the seeding activity of α-synuclein both between different patients and between different brain regions.
METHODS
The reliable detection of α-synuclein seeding activity derived from MSA using cell-free amplification assays remains challenging. Therefore, we conducted a systematic evaluation of 168 different reaction buffers, using an array of pH and salts, seeded with fully characterized brain homogenates from one MSA and one PD patient. We then validated the two conditions that conferred the optimal ability to discriminate between PD- and MSA-derived samples in a larger cohort of 40 neuropathologically confirmed cases, including 15 MSA. Finally, in a subset of brains, we conducted the first multi-region analysis of seeding behaviour in MSA.
RESULTS
Using our novel buffer conditions, we show that the physicochemical factors that govern the in vitro amplification of α-synuclein can be tailored to generate strain-specific reaction buffers that can be used to reliably study the seeding capacity from MSA-derived α-synuclein. Using this novel approach, we were able to sub-categorize the 15 MSA brains into 3 groups: high, intermediate and low seeders. To further demonstrate heterogeneity in α-synuclein seeding in MSA, we conducted a comprehensive multi-regional evaluation of α-synuclein seeding in 13 different regions from 2 high seeders, 2 intermediate seeders and 2 low seeders.
CONCLUSIONS
We have identified unexpected differences in seed-competent α-synuclein across a cohort of neuropathologically comparable MSA brains. Furthermore, our work has revealed a substantial heterogeneity in seeding activity, driven by the PBS-soluble α-synuclein, between different brain regions of a given individual that goes beyond immunohistochemical observations. Our observations pave the way for future subclassification of MSA, which exceeds conventional clinical and neuropathological phenotyping and considers the structural and biochemical heterogeneity of α-synuclein present. Finally, our methods provide an experimental framework for the development of vitally needed, rapid and sensitive diagnostic assays for MSA.
Identifiants
pubmed: 35125105
doi: 10.1186/s40035-022-00283-4
pii: 10.1186/s40035-022-00283-4
pmc: PMC8819887
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
© 2022. The Author(s).
Références
Ann Neurol. 2019 May;85(5):691-703
pubmed: 30805957
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Acta Neuropathol. 2021 Jul;142(1):73-86
pubmed: 32440702
J Clin Pathol. 2019 Nov;72(11):725-735
pubmed: 31395625
J Neurol Neurosurg Psychiatry. 1969 Feb;32(1):28-34
pubmed: 5774131
Acta Neuropathol. 2021 Jul;142(1):87-115
pubmed: 33978813
Acta Neuropathol. 2012 Jul;124(1):37-50
pubmed: 22370907
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4949-58
pubmed: 26286986
Nat Protoc. 2016 Nov;11(11):2233-2242
pubmed: 27735933
Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):23029-23039
pubmed: 31641070
Curr Opin Neurobiol. 2020 Apr;61:89-95
pubmed: 32112991
JAMA Neurol. 2017 Feb 1;74(2):155-162
pubmed: 27942718
Nature. 2018 May;557(7706):558-563
pubmed: 29743672
Nat Neurosci. 2020 Jan;23(1):21-31
pubmed: 31792467
Acta Neuropathol. 2000 Sep;100(3):235-44
pubmed: 10965792
JAMA Neurol. 2020 Sep 28;:
pubmed: 32986090
J Neurol Sci. 1989 Dec;94(1-3):79-100
pubmed: 2559165
Biomolecules. 2020 Aug 25;10(9):
pubmed: 32854212
Neuropathology. 2021 Feb;41(1):72-83
pubmed: 33263220
Ann Neurol. 2019 May;85(5):777-781
pubmed: 30801759
Nat Med. 2020 Aug;26(8):1256-1263
pubmed: 32572268
Ann Neurol. 2020 Sep;88(3):503-512
pubmed: 32557811
Am J Pathol. 1999 Oct;155(4):1241-51
pubmed: 10514406
Nature. 2015 Jun 18;522(7556):340-4
pubmed: 26061766
J Neurochem. 2001 Jan;76(1):87-96
pubmed: 11145981
Mov Disord. 2020 Feb;35(2):268-278
pubmed: 31758740
Acta Neuropathol. 2019 Mar;137(3):455-466
pubmed: 30721406
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
Transl Neurodegener. 2020 Jan 17;9:5
pubmed: 31988747
Nature. 2020 Feb;578(7794):273-277
pubmed: 32025029
Brain. 2004 Dec;127(Pt 12):2657-71
pubmed: 15509623
Nature. 2020 Sep;585(7825):464-469
pubmed: 32461689
Clin Lab Med. 2020 Sep;40(3):257-270
pubmed: 32718498
Acta Neuropathol. 1997 Jun;93(6):585-91
pubmed: 9194897
Neurosci Lett. 1998 Jul 31;251(3):205-8
pubmed: 9726379